The companies are competing in the weight loss drug market.

Novo got a much-needed boost from its latest earnings report.

Novo Nordisk is looking to build a volume-driven business, but the successful launch of the Wegovy pill is just the first ...

Novo released new evidence that its experimental CagriSema injection can improve upon the weight loss with its blockbuster GLP-1 obesity injection, Wegovy.

At the American Heart Association conference, investigators were supportive of further studying Novo’s IL-6 inhibitor ...

"The Wegovy pill has exceeded our expectations," Novo Nordisk CEO Mike Doustdar said on Sozzi Unleashed. Doustdar said the ...

Novo Nordisk shows commercial recovery with accelerating patient additions in obesity and diabetes. Read why NVO stock is a ...

Novo Nordisk offers 34% upside as Q3 results ease oral cannibalization fears. Read why I am optimistic about the upside to ...

Novo Nordisk shares surged Wednesday on a single metric from the Wegovy earnings call that suggested the oral pill is ...

On 6 May 2026, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of ...

The Swedish drug-delivery company agreed to license its PharmaShell technology to Novo Nordisk for up to five development programs targeting obesity, type 2 diabetes and other cardiometabolic ...

Randa Kriss is a senior writer and NerdWallet authority on small business. She has nearly a decade of experience in digital content. Prior to joining NerdWallet in 2020, Randa worked as a writer at ...